Trial Profile

A Phase 2 Study of Galicaftor/Navocaftor/ABBV-119 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 22 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABBV-119 (Primary) ; Galicaftor (Primary) ; Navocaftor (Primary)
Indications Cystic fibrosis
Focus Therapeutic Use
Sponsors AbbVie; AbbVie Germany

Most Recent Events

21 Jun 2023 Status changed from active, no longer recruiting to discontinued.
28 Apr 2023 Planned End Date changed from 11 Nov 2023 to 7 Jun 2023.
28 Apr 2023 Planned primary completion date changed from 16 Oct 2023 to 7 Jun 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com